#United States #New York #Armata Pharmaceuticals #Bacteriophage Therapy #H.C. Wainwright

Armata Pharmaceuticals to Participate in H.C. Wainwright Conference

Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a pioneering clinical-stage biotechnology firm, is gearing up for a significant presence at the H.C. Wainwright 27th Annual Global Investment Conference to be held in New York from September 8-10, 2025. The company specializes in the development of high-purity, pathogen-specific bacteriophage therapeutics aimed at combating antibiotic-resistant bacterial infections, a critical area of healthcare that affects countless individuals globally.

Overview of the Conference

The conference, known for bringing together leading healthcare companies and investors, will feature Armata's Chief Executive Officer, Dr. Deborah Birx. Dr. Birx is scheduled to deliver a corporate presentation about Armata’s latest advancements in bacteriophage therapy on Wednesday, September 10, from 1:30 PM to 2:00 PM ET. This presentation promises to shed light on the company’s innovative strategies in addressing challenging bacterial infections and their ongoing research in phage therapy.

Armata's Innovative Approach

What sets Armata apart is its commitment to harnessing bacteriophage—a natural virus that infects and kills bacteria—as a viable treatment option. Bacteriophage therapy represents a powerful alternative to traditional antibiotics, particularly as many bacterial species develop resistance to conventional antibiotics. Armata Pharmaceuticals is firmly positioned to impact the treatment landscape with a robust pipeline that includes candidates targeting notable pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.

The company employs advanced proprietary technologies to engineer both natural and synthetic phage candidates. These therapies are designed to tackle resistant infections more effectively than traditional methods, providing a beacon of hope in an era of rising antibiotic resistance.

In addition to innovative treatment avenues, Armata emphasizes comprehensive drug development expertise that spans the entire process from research bench to clinical settings. Their in-house facilities are equipped to adhere to current Good Manufacturing Practices (cGMP), ensuring that the manufacturing processes meet the highest standards of safety and efficacy required for the commercial rollout of these treatments.

Investment and Future Directions

Armata’s participation in the H.C. Wainwright conference signifies not just an opportunity for the company to showcase its advancements but also a chance to engage directly with potential investors. Businesses within the clinical stage often find this kind of exposure pivotal for securing funding needed to support ongoing research and development.

As the global landscape continues to grapple with antibiotic resistance, the solutions Armata Pharmaceuticals is pursuing may change patient outcomes and redefine therapeutic options. Investors, industry professionals, and the medical community will closely watch for insights into the company’s strategy and innovative progress during this significant event.

To schedule a one-on-one meeting with Armata’s representatives during the conference, interested parties are encouraged to reach out to their H.C. Wainwright contacts for potential discussions.

For further updates and information regarding Armata Pharmaceuticals, continue to follow their press releases and official announcements as they progress in their mission to advance health solutions through innovative bacteriophage technology. This initiative places Armata at the forefront of a revolutionary approach in the fight against bacterial infections, illustrating their commitment to improving public health outcomes.

For media inquiries, please contact Pierre Kyme at Armata Pharmaceuticals or reach out to Joyce Allaire at LifeSci Advisors, LLC, whose detailed contact information can be found in their official press release.